Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Abstract The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~ 300 amino acid receptor binding domain...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Asheley P. Chapman, Xiaoling Tang, Joo R. Lee, Asiya Chida, Kristina Mercer, Rebekah E. Wharton, Markus Kainulainen, Jennifer L. Harcourt, Roosecelis B. Martines, Michelle Schroeder, Liangjun Zhao, Anton Bryksin, Bin Zhou, Eric Bergeron, Brigid C. Bollweg, Azaibi Tamin, Natalie Thornburg, David E. Wentworth, David Petway, Dennis A. Bagarozzi, M. G. Finn, Jason M. Goldstein
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/62c76690f37c478981f0b0dd9033fece
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares